Pure Global AI
NCT06084156Completed

A Study to Evaluate the DDI of HSK7653 With Metformin

A Phase I Clinical Study to Evaluate the Drug-Drug Interaction Between HSK7653 and Metformin in Healthy Subjects
Haisco Pharmaceutical Group Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Type 2 Diabetes Mellitus
Drug/Device/Intervention
HSK7653
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Haisco Pharmaceutical Group Co., Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Aug 10, 2019
End date
Dec 09, 2019
Enrollment
22 participants
Primary outcome

The primary pharmacokinetics parameter of Cmax To assess the potential pharmacokinetic interaction between HSK7653 and metformin in health subjects.,The primary pharmacokinetics parameter of AUC To assess the potential pharmacokinetic interaction between HSK7653 and metformin in health subjects.

Summary

This is a Phase 1, single center, open-label, single arm, drug-drug interaction study of
 HSK7653 and metformin in Healthy Subjects.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06084156
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06084156 through Pure Global AI's free database. This Phase 1 trial is sponsored by Haisco Pharmaceutical Group Co., Ltd. and is currently Completed. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 22 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.